首页 / 院系成果 / 成果详情页

Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites  期刊论文  

  • 编号:
    c3ada457-59e4-4462-8702-bb4089b157e9
  • 作者:
    Liu, Jiang#[1]Ding, Zhaoli#[2,3]Li, Guimei#[2,3]Tang, Li[1];Xu, Yu[4];Luo, Huayou[4];Yi, Jinhua[4];Lu, Youwang[4];Mao, Rui(毛瑞)[5]Nan, Qiong(南琼)[6]Ren, Li[7];Zhang, Tong[4];Wang, Kunhua*[4]
  • 语种:
    英文
  • 期刊:
    ONCOTARGET ISSN:1949-2553 2017 年 8 卷 69 期 (114183 - 114194) ; DEC 26
  • 收录:
  • 关键词:
  • 摘要:

    To date, the sensitivity of currently available biomarkers based on the methylation of gene promoters is suboptimal for detecting adenomas and earlystage colorectal cancer (CRC). We aimed to develop biomarkers with methylated DNA binding sites of the multifunctional transcriptional factor CTCF for early detection of CRC. Using combined analyses of genome-wide occupation and the methylation profile of CTCF-binding sites, we identified candidate CTCF-binding sites. Then, we applied methylation-sensitive high-resolution melting (MS-HRM) and mass spectrometry analysis to screen and validate these candidate sites in diverse sample sets. We identified a set of colorectal neoplasia-specific biomarkers with robust performance. The top five biomarkers were selected and recommended for early detection of colorectal neoplasia. All of the five novel biomarkers exhibited a more robust discriminatory performance than that by BMP3 and NDRG4, two currently acknowledged robust methylation biomarkers. When the five new biomarkers were considered as a marker panel and tumor-positive was defined as having two or more (of the five) positive biomarkers, the marker panel could achieve a sensitivity of 91.67% for adenomas, 97.44% for Stage I CRC, 94.06% for Stage II CRC, 93.62% for Stage III CRC, and 93.54% for total colorectal tumors with a specificity of 94.05%. To our knowledge, this is the first study for colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites. Using a similar strategy, CTCF-binding sites could be potentially developed into biomarkers for other tumors. In summary, this study opens a new area in developing biomarkers for tumor prevention and treatment.

  • 推荐引用方式
    GB/T 7714:
    Liu Jiang,Ding Zhaoli,Li Guimei, et al. Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites [J].ONCOTARGET,2017,8(69):114183-114194.
  • APA:
    Liu Jiang,Ding Zhaoli,Li Guimei,Tang Li,&Wang Kunhua.(2017).Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites .ONCOTARGET,8(69):114183-114194.
  • MLA:
    Liu Jiang, et al. "Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites" .ONCOTARGET 8,69(2017):114183-114194.
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:327 下载次数:0
浏览次数:327
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部